Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The JointJYNT -3.64%62 3-Year EBITDA Growth Rate is -53.60% as of Mar. 2026. GuruFocus rates JYNT with a GF Score™ of 62/100 and a GF Value™ of $11.26 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 527 Healthcare Providers & Services companies, The Joint ranks worse than 97.53% on this metric.
During the past 12 months, The Joint's average EBITDA Per Share Growth Rate was 57.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -53.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -35.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of The Joint was 60.60% per year. The lowest was -78.40% per year. And the median was 2.00% per year.
The Joint (NAS:JYNT) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
The Joint 3-Year EBITDA Growth Rate Related Terms
JYNT vs WW, PARK, BTMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, The Joint's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where The Joint's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -53.60% mean?
The Joint (JYNT) has a 3-Year EBITDA Growth Rate of -53.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Joint and its competitors. According to the industry distribution chart, The Joint ranks #514 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 97.5%.
Is The Joint's 3-Year EBITDA Growth Rate too high?
The Joint's current 3-Year EBITDA Growth Rate is -53.60%. Based on the distribution chart, The Joint ranks #514 out of 527 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, The Joint has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's 3-Year EBITDA Growth Rate compare to WW and PARK?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #514 out of 527 companies for 3-Year EBITDA Growth Rate. This places The Joint in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Joint and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current 3-Year EBITDA Growth Rate is -53.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.26, compared to a current price of $8.34 — trading 25.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -53.60%. The Joint's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For The Joint (JYNT), the current 3-Year EBITDA Growth Rate is -53.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.34 is trading 25.9% below its estimated GF Value™ of $11.26.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
3-Year EBITDA Growth Rate: -53.60%
GF Value™: $11.26 vs. price of $8.34 (25.9% below fair value)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
62GF Score
Get the complete analysis for JYNT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
